NEW YORK and NOIDA, India, Feb. 27, 2026 /PRNewswire/ — HCLTech, (NSE: HCLTECH) (BSE: HCLTECH) a leading global technology company, will showcase how the next era of telecom, media and technology (TMT) is being built on AI–native architectures and industry convergence, at Mobile World Congress Barcelona 2026. HCLTech will bring together senior industry leaders, hyperscaler partners, academics and innovators to highlight how intelligence, scale and ecosystem collaboration are powering sustainable AI–driven growth for the TMT sector.

Industry leaders from Microsoft, Nokia, Ericsson, AT&T, Verizon, PwC, Bain, Axiata, Singtel, MasOrange, Liberty Latin America and other global organizations will engage in these impactful conversations, focusing on strategic shifts that are enabling AI–native transformation, autonomous operations, platform-driven experiences and ecosystem-led innovation.

HCLTech’s presence at MWC will spotlight:

• Executive panels and CXO conversations: High–level discussions framing the strategic shifts driving the converged TMT ecosystem—from embedding AI across core operations to unlocking platform–driven business models and autonomous infrastructure—alongside a flagship roundtable hosted in partnership with GSMA and moderated by Prof. Saikat Chaudhuri, Faculty Director of the Management, Entrepreneurship and Technology (M.E.T.) program at UC Berkeley.
• Live demonstrations: Hands-on showcases of intelligent networks engineered for zero-failure environments, AI-powered media and digital platforms delivering real-time insights, and automation frameworks such as Agentic fraud management, AI-powered Operations Support Systems (OSS) Solutions for Telco, HCLTech’s GenAI service transformation platform, AI Force, Agentic AI solutions, and AIOps to enhance operational efficiency, and agentic-powered Contact Center as a Service platform for smarter customer engagement.
• Startup and partner innovation: Emerging companies advancing AI, digital marketplaces and cybersecurity analytics, alongside hyperscaler partnerships and co-innovation initiatives that accelerate transformation at scale.
• Telecom industry survey on AI priorities: To be revealed following MWC, HCLTech will preview findings from a Mobile World Live survey on AI and technology priorities for telecom organizations, offering real-world insights into how executives are planning investments and strategy in the intelligence era.

“It’s an exciting moment for the industry as convergence and AI are redefining networks, platforms and business models,” said Anil Ganjoo, Chief Growth Officer and Global Head of Telecom, Media and Technology at HCLTech. “By combining AI, cloud and digital engineering expertise with ecosystem partnerships, we are helping enterprises build resilient, scalable and intelligence-driven systems for sustainable growth.”

“HCLTech’s leadership at MWC, bringing together enterprise, hyperscaler and academic voices, captures the strategic imperative of AI–native transformation,” said Prof. Saikat Chaudhuri, Faculty Director of the Management, Entrepreneurship and Technology (M.E.T.) program at UC Berkeley. “Their approach to integrating AI across infrastructure, platforms and ecosystems is empowering sustainable AI–driven growth for the TMT sector.”

Attendees can explore these discussions, innovations and insights at Hall 2, Stand 2E19, during MWC Barcelona 2026, March 2-5. For more information, visit: https://www.hcltech.com/events/mwc-barcelona

About HCLTech

HCLTech is a global technology company, home to more than 226,300 people across 60 countries, delivering industry-leading capabilities centered around AI, digital, engineering, cloud and software, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG, Mobility and Public Services. Consolidated revenues as of 12 months ending December 2025 totaled $14.5 billion. To learn how we can supercharge progress for you, visit hcltech.com.

For further details, please contact:

Meredith Bucaro, Americas
meredith-bucaro@hcltech.com

Elka Ghudial, EMEA
elka.ghudial@hcltech.com

James Galvin, APAC
james.galvin@hcltech.com

Nitin Shukla, India
nitin-shukla@hcltech.com

Source

HO CHI MINH CITY, Vietnam, Feb. 26, 2026 /PRNewswire/ — VT Markets has successfully completed a community initiative in Vietnam, donating 100 official Newcastle United Football Club (NUFC) footballs to local youth groups in partnership with a youth-focused non-profit organisation named Liên Đoàn Hướng Đạo Nguyễn Trãi.

The initiative reflects the company’s expanding commitment to community development across Asia and forms part of a broader CSR line-up unveiled during its July 2025 event.

Designed to strengthen youth engagement, the donation provides students with quality equipment to support physical education and grassroots football development, helping create a more inspiring and inclusive sporting environment.

In collaboration with Liên Đoàn Hướng Đạo Nguyễn Trãi, footballs were distributed directly to selected communities, ensuring access to students who stand to benefit most from enhanced sporting resources. By supporting grassroots participation, the programme aims to create a more inclusive environment where young people can develop confidence, build friendships, and stay actively engaged in their communities.

“Sport has the power to inspire discipline, teamwork, and resilience – values that extend far beyond the pitch. Through this initiative, we hope to contribute meaningfully to youth development and community growth in Vietnam”, Dandelyn Koh, Head of Global Marketing at VT Markets said.

In recent months, the company has intensified its regional engagement through a series of on-the-ground initiatives, including beach clean-up campaigns and flood relief pack donations aimed at supporting vulnerable communities. With programmes already planned for the new year, VT Markets remains dedicated to deepening its local footprint, reinforcing its role not only as a global financial partner but also as a responsible and proactive community stakeholder.

About VT Markets

VT Markets is a regulated multi-asset broker with a presence in over 160 countries as of today. It has earned numerous international accolades including Best Online Trading and Fastest Growing Broker. In line with its mission to make trading accessible to all, VT Markets offers comprehensive access to over 1,000 financial instruments and clients benefit from a seamless trading experience via its award-winning mobile application.

For more information, please visit the official VT Markets website or email us at info@vtmarkets.com. Alternatively, follow VT Markets on Facebook, Instagram, or LinkedIn.

Source

Source: Zuler Technology Pte. Ltd

Source

GENEVA, Feb. 25, 2026 /PRNewswire/ — As the creator economy continues to mature, content monetization platforms are entering a new phase of structural development. The rapid growth of the sector is now accompanied by increased professionalization: dedicated teams, automation tools, outsourced management, and advanced technological solutions have become embedded in the ecosystem.

Your fans deserve the real you, not AI chats. Join RedPeach. Verified creators only.

In France, the Senate is currently reviewing measures aimed at regulating what some lawmakers have referred to as “Pimping 2.0,” a term used to describe outsourced profile management and delegated user interactions on certain subscription-based platforms. The debate, covered by RTL, extends beyond France and reflects a broader European and international movement toward stronger transparency requirements, intermediary accountability, and enhanced creator protections. As regulators take a closer look at opaque delegation models and automated interaction systems, compliance standards are expected to tighten.

In this environment, RedPeach designed to prevent undisclosed delegation and ensure interaction authenticity positions itself in alignment with emerging regulatory expectations.

While this evolution follows a clear economic logic, it also raises a strategic question: how can clarity and trust be maintained in digital interactions when multiple layers of intervention may operate behind a single account?

It is within this context that the Swiss company RedPeach is developing a verification-centered approach: https://redpeach.com/face-verification.

The platform has developed proprietary technology that integrates a facial validation mechanism within private messaging. The objective is to certify that responses originate directly from the account holder, thereby reinforcing interaction traceability and transparency.

“The creator economy has grown extremely fast. We believe the next stage is not only about growth, but about clarity. Technology should strengthen trust in interaction, not replace it,” said Marco Cally, CEO of RedPeach.

As part of its development strategy, the RedPeach team conducted a six-month study analyzing 2,000 publicly accessible creator accounts operating on subscription-based platforms.

According to the company’s internal findings, 65% of accounts generating between $500 and $100,000 in monthly revenue appear to rely on external management structures or technological assistance tools to manage user interactions (internal analysis; methodology and scope available upon request).

Beyond its verification infrastructure, RedPeach’s 2026 roadmap is part of a broader responsible innovation framework: enhanced content protection tools, collaborative features for creators, diversified payment solutions, and structured support programs.

Originally developed as a CRM solution and payment infrastructure for freelancers and small and mid-sized businesses, RedPeach technology has evolved to address the specific needs of the creator economy, particularly as expectations around transparency and digital accountability continue to increase.

Rather than positioning itself in opposition to existing platforms, RedPeach presents its model as a technological evolution of the sector: a framework in which technical validation of interactions contributes to a clearer and more sustainable environment for content monetization.

About RedPeach

Founded in Geneva, RedPeach is a content monetization technology platform built around interaction verification mechanisms and secure infrastructures aligned with current digital standards.

Learn More

Website: https://redpeach.com
Explanatory Page: https://redpeach.com/face-verification
Recent Interview: https://www.lebigdata.fr/onlyfans-ia-et-scam-emotionnel-industrialisent-lintimite

Source

TAIPEI, Feb. 25, 2026 /PRNewswire/ — World Gym Corporation (2762.TW) (“World Gym” or the “Company”), the owner of the iconic World Gym brand with over 280 locations worldwide, today announced that its President, John Caraccio, and Executive Committee Member, Mark Harms, will participate in a Fireside Chat with IPO Edge and The Palm Beach Hedge Fund Association on February 27 at 8:00 am Eastern Time.

During the event, Messrs. Caraccio and Harms will discuss the company’s recent Q4 and full year 2025 financial performance as well as outlook for 2026. The Company is experiencing rapid acceleration of revenue and earnings growth due to its disciplined growth strategy, combined with stringent cost controls and has plans to add many new locations as well as offer innovative services. The live event will be moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasting approximately 60 minutes including a Q&A with the audience.

“I look forward to participating in this event and offering more color about our financial results as well as diving into some of the exciting things we have on the horizon, such as our focus on AI and longevity and more,” said John Caraccio, President of World Gym Corporation.

About World Gym Corporation

World Gym Corporation is Taiwan’s largest fitness chain, operating 139 locations. In 2024, it acquired World Gym International, securing the iconic World Gym brand and global operating rights, establishing itself as a global fitness leader. With a franchise network spanning 10 countries and 284 locations, it serves 900,000 members. The company continues to empower individuals worldwide to achieve their fitness goals and live healthier lives through state-of-the-art facilities, innovative programs, and technology-driven solutions.

Source

SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.

This collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037. At a time when resistance to checkpoint inhibitors (CPIs) has become a major clinical challenge, the Phase I study evaluating ATG-037 in combination with CPIs has already demonstrated promising potency into reversing CPI resistance. Beyond validating the synergistic potential of these two innovative drugs, this collaboration aims to advance the efficacy of existing immunotherapies and extend the overall survival (OS) of cancer patients through a “triple-axis” approach that incorporates immune checkpoint signalling, anti-angiogenesis, and the alleviation of adenosine-mediated immunosuppression.

ATG-037, Antengene’s orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the “hook effect” commonly observed with antibody-based approaches. In addition, ATG-037’s higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level. ATG-037 has demonstrated encouraging clinical activity in combination with anti–PD-1 therapy in patients with CPI-resistant melanoma and non-small cell lung cancer (NSCLC), based on the latest data presented at Antengene’s R&D Day in November 2025. In the ongoing Phase I/Ib STAMINA-01 study, the combination achieved an objective response rate (ORR) of 33.3% with a disease control rate (DCR) of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037’s clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy. Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037’s potential role as a backbone agent for next-generation immuno-oncology combination regimens.

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207’s preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207’s antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1. In a poster presented at ESMO Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive NSCLC received JS207 monotherapy as first-line treatment, and achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies, antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative NSCLC.

The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti–PD-1 monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential “triple-axis” approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved OS.

We look forward to working closely with Junshi Biosciences and leveraging our respective expertise in target biology and clinical development to accelerate the evaluation of ATG-037 in combination with JS207 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Mainland China.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com

Source